BioCardia Yönetim

Yönetim kriter kontrolleri 3/4

BioCardia CEO'su Peter Altman, Jan2002 tarihinde atandı, in görev süresi 22.58 yıldır. in toplam yıllık tazminatı $ 746.24K olup, şirket hissesi ve opsiyonları dahil olmak üzere 69.1% maaş ve 30.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.87% ine doğrudan sahiptir ve bu hisseler € 98.58K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 8.4 yıl ve 7.8 yıldır.

Anahtar bilgiler

Peter Altman

İcra Kurulu Başkanı

US$746.2k

Toplam tazminat

CEO maaş yüzdesi	69.1%
CEO görev süresi	22.6yrs
CEO sahipliği	1.9%
Yönetim ortalama görev süresi	8.4yrs
Yönetim Kurulu ortalama görev süresi	7.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Peter Altman'un ücretlendirmesi BioCardia'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$9m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$746k	US$516k	-US$12m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$902k	US$531k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$1m	US$488k	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$13m
Mar 31 2021	n/a	n/a	-US$13m
Dec 31 2020	US$883k	US$380k	-US$15m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$747k	US$363k	-US$15m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$15m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$1m	US$360k	-US$14m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$13m
Dec 31 2017	US$372k	US$310k	-US$12m

Tazminat ve Piyasa: Peter 'nin toplam tazminatı ($USD 746.24K ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 471.14K ).

Tazminat ve Kazançlar: Peter 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Peter Altman (57 yo)

22.6yrs

Görev süresi

US$746,237

Tazminat

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Altman	CEO, President & Director	22.6yrs	US$746.24k	1.87% € 98.6k
David McClung	Chief Financial Officer	8.4yrs	US$469.47k	0.43% € 22.4k
Edward Gillis	Senior Vice President of Devices	3.8yrs	US$326.37k	0.15% € 8.1k

8.4yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 6JU0 'un yönetim ekibi deneyimli ve deneyimlidir ( 8.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Peter Altman	CEO, President & Director	22.6yrs	US$746.24k	1.87% € 98.6k
Jay Moyes	Independent Director	13.6yrs	US$65.29k	0.17% € 9.0k
Richard Krasno	Independent Director	7.8yrs	US$57.79k	0.15% € 7.8k
William Facteau	Independent Director	less than a year	US$24.69k	Veri yok
Simon Stertzer	Independent Director	22.6yrs	US$47.55k	4.68% € 246.3k
Jim Allen	Independent Director	4.8yrs	US$49.29k	2.81% € 148.0k
Andrew Blank	Independent Chairman	4.8yrs	US$97.79k	1.58% € 83.2k

7.8yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6JU0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.8 yıldır).

BioCardia Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

BioCardia, Inc., Annual General Meeting, May 20, 2024

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Insider recently bought €164k worth of stock

Insufficient new directors

Recent updates

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Regains Full Compliance with Nasdaq Capital Market's Listing Requirements

BioCardia, Inc. Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

BioCardia, Inc. Announces Fda Approves Cardiamp®? Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

BioCardia, Inc. Submits for FDA Approval of Morph®? DNA™? Steerable Introducer Product Family

BioCardia, Inc. Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

New major risk - Shareholder dilution

First quarter 2024 earnings released: US$0.09 loss per share (vs US$0.17 loss in 1Q 2023)

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

Full year 2023 earnings released: US$0.55 loss per share (vs US$0.67 loss in FY 2022)

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.17 loss in 3Q 2022)

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

New major risk - Revenue size

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.14 loss in 2Q 2022)

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

Insider recently bought €164k worth of stock

First quarter 2023 earnings released: US$0.17 loss per share (vs US$0.20 loss in 1Q 2022)

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.67 loss per share (vs US$0.75 loss in FY 2021)

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Insufficient new directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.16 loss in 3Q 2021)

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Second quarter 2022 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2021)

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.18 loss in 1Q 2021)

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings released: US$0.75 loss per share (vs US$1.48 loss in FY 2020)

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

BioCardia®, Inc Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.30 loss in 3Q 2020)

BioCardia, Inc. Announces Data from Its CardiAMP® Cell Therapy Heart Failure Pivotal Trial to Present at the Heart Failure Society of America Annual Meeting 2021 on September 11, 2021

Second quarter 2021 earnings released: US$0.20 loss per share (vs US$0.46 loss in 2Q 2020)

Biocardia Announces Japanese Patent on Imaging System for Targeting Cardiac Therapies

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal Cardiamp Cell Therapy Heart Failure Study as Designed

BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.67 loss in 1Q 2020)

Full year 2020 earnings released: US$1.48 loss per share (vs US$2.61 loss in FY 2019)